Proteon Pharmaceuticals
Proteon Pharmaceuticals is an innovative biotech company.
- Company typePrivate
- Founded2005
- HeadquartersLodz, Poland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Proteon Pharmaceuticals does
PROTEON uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. We have developed a platform to develop and deliver bacteriophages for animal health solutions. Our pipeline includes solutions to prophylactically improve performance and food safety in poultry, as well as important prevent economically important bacterial diseases in aquaculture and dairy.
Proteon Pharmaceuticals firmographics
Firmographics- Name
- Proteon Pharmaceuticals
- Legal name
- Proteon Pharmaceuticals S.A.
- Website
- http://proteonpharma.com/
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Proteon Pharmaceuticals is an innovative biotech company.
- Ownership category
- akta.pro rank
Proteon Pharmaceuticals industry classification
Industry- Product category
- Animal Health Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support) (AFADALAO)
- akta.pro secondary industries
- Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE), Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE)
Keywords
Where Proteon Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Lodz
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Proteon Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Bacteriophage-based Solutions: The company generates revenue through the sale of bacteriophage-based products and solutions for the aquaculture and livestock markets. These products are designed to reduce antibiotic use in farming, targeting sustainable and health-conscious protein production globally.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Proteon Pharmaceuticals product offering
Product offeringCore offering
Proteon Pharmaceuticals develops and sells bacteriophage-based products for livestock and aquaculture that serve as alternatives to traditional antibiotics in animal farming. The company applies its microbiome platform technology—integrating AI, high-throughput screening, and process automation—to identify and produce targeted bacteriophage formulations that maintain animal health and support sustainable protein production. Its offerings are aimed at large-scale farming operations seeking to reduce antibiotic use amid regulatory and market pressure for sustainable practices.
Product overview
Proteon Pharmaceuticals offers bacteriophage-based solutions for livestock and aquaculture. Their microbiome platform technology provides sustainable alternatives to antibiotics in agriculture, targeting animal health and sustainable protein production. The company develops solutions aimed at reducing antibiotic use in livestock farming and aquaculture. No individual named products or modules are explicitly identified in the available sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Bacteriophage-based solutions for livestock and aquaculture
Quantifiable outcome
- Reduction of antibiotic use in agriculture
- +2 more outcomes
Companies that use Proteon Pharmaceuticals
Customer profileSegments2 records
Ideal customer profiles2 records
Proteon Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Proteon Pharmaceuticals partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Proteon Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Phagelux: Phagelux develops bacteriophage-based products targeting animal health, food safety, and agricultural applications. It is the closest direct competitor to Proteon in animal/agriculture phage products, addressing similar customer pain points around antibiotic reduction.
- Intralytix: Intralytix is a pioneer in bacteriophage products, with animal health and food safety applications. Its overlapping product categories and phage R&D capability make it a direct comparable to Proteon.
- Micreos: Micreos develops phage-based applications targeting bacteria across food safety and animal health. Its commercialization model in animal protein supply chains closely mirrors Proteon's positioning.
- Fixed Phage: Fixed Phage is a UK-based phage technology company applying bacteriophages to animal health and agricultural challenges. Its narrow focus on phage technology for livestock and aquaculture makes it a direct comparable.
Emerging players
- Eligo Bioscience: Eligo Bioscience engineers phage-based products to modulate microbiomes, including in animal health applications. It is an emerging player with overlapping platform technology to Proteon's microbiome approach.
- BiomX: BiomX develops phage-based therapies primarily for human health but applies a similar phage discovery and engineering platform. Its technology approach is thematically comparable to Proteon's AI-driven phage platform.
- Locus Biosciences: Locus Biosciences develops engineered bacteriophage products for antimicrobial applications. Its platform-based approach to phage R&D is comparable to Proteon's high-throughput screening and AI integration strategy.
Broad incumbents
- Elanco Animal Health: Elanco is a large incumbent in animal health and nutrition with broad portfolios in livestock and aquaculture. It competes with Proteon as a buyer-facing supplier and could acquire or displace phage-based alternatives.
- Zoetis: Zoetis is the world's largest animal health company, offering vaccines, diagnostics, and feed additives across livestock and aquaculture. It represents the broad incumbent competitive threat to niche phage developers like Proteon.
- Phibro Animal Health: Phibro Animal Health supplies nutritional and health products for livestock and aquaculture, including antibiotic alternatives. Its incumbent position in animal protein supply chains makes it a relevant comparator for go-to-market dynamics.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights5 records
Customer concentration
Proteon Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proteon Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles9 records
Proteon Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proteon Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proteon Pharmaceuticals
What does Proteon Pharmaceuticals do?
Proteon Pharmaceuticals develops and sells bacteriophage-based products for livestock and aquaculture that serve as alternatives to traditional antibiotics in animal farming. The company applies its microbiome platform technology—integrating AI, high-throughput screening, and process automation—to identify and produce targeted bacteriophage formulations that maintain animal health and support sustainable protein production. Its offerings are aimed at large-scale farming operations seeking to reduce antibiotic use amid regulatory and market pressure for sustainable practices.
Is Proteon Pharmaceuticals a public or private company?
Proteon Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Proteon Pharmaceuticals founded?
Proteon Pharmaceuticals was founded in 2005. It employs 51 to 100 people.
Where is Proteon Pharmaceuticals based?
Proteon Pharmaceuticals is headquartered in Lodz, Poland, in the Europe region.
How does Proteon Pharmaceuticals make money?
One revenue line is on record: bacteriophage-based Solutions.
Who are Proteon Pharmaceuticals's main competitors?
Direct peers on record are Phagelux, Intralytix, Micreos and Fixed Phage. Emerging players are Eligo Bioscience, BiomX and Locus Biosciences. Broad incumbents are Elanco Animal Health, Zoetis and Phibro Animal Health.
Does Proteon Pharmaceuticals have an API?
No public API is recorded for Proteon Pharmaceuticals.
What industry is Proteon Pharmaceuticals in?
Proteon Pharmaceuticals's product category is Animal Health Biologics. Its primary akta.pro industry code is AFADALAO, Non-Antibiotic Health & Performance Supplements (Immune, Gut Health, Stress/Heat Support), with a secondary code of AFADALAE, Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials). Its NAICS code is 325414 and its SIC code is 2836.